Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474515 | 0.93 | EGFR (0.56) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14474856 | 0.93 | FBP1 (0.57) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14726657 | 0.93 | EGFR (0.56) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14474417 | 0.93 | EPHA2 (0.61) | KDRABCB1ABCG2EPHB4ERBB2 | |
| SCHEMBL14726636 | 0.93 | ABCG2 (0.58) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14474871 | 0.92 | ABCG2 (0.63) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14474145 | 0.88 | ABCG2 (0.60) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14474473 | 0.87 | ABCG2 (0.57) | EGFRKDRABCB1ABCG2EPHB4 | |
| SCHEMBL14475411 | 0.86 | ABCG2 (0.54) | EGFRABCB1ABCG2ERBB2 | |
| SCHEMBL14474839 | 0.85 | ABCG2 (0.59) | EGFRKDRABCB1ABCG2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | EGFR 1667/4885KDR 3024/4885ABCB1 4803/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | EGFR 1000/4885KDR 2226/4885ABCB1 4758/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | EGFR 1667/4885KDR 3024/4885ABCB1 4803/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | EGFR 3702/4885KDR 4383/4885ABCB1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.